Skip to content
value.today

Aileron Therapeutics Inc.

Total raised
$93 M
4 rounds on record
Latest round
$30 M
Dec 2016
First round on record
May 2009
Today
Went public
See the company page

Aileron Therapeutics Inc. is listed today as Rein Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Aileron Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$18 MPrivate placement after listing$10 to $50 million

Aileron Therapeutics Inc.: Private sale, Nov 2023

Investors in this round

15 investors had bought by the notice of Nov 16, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Aileron Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$752,797
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Windsor, Ph.D. · Executive Officer
  • Manuel Alves-Aivado, M.D., Ph.D. · Executive Officer, Director
  • Susan L. Drexler · Executive Officer
  • Alan H. Musso · Director
  • Josef H. von Rickenbach · Director
  • Nolan H. Sigal, M.D., Ph.D. · Director
  • Reinhard J. Ambros · Director
  • William H. Fairey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in CT, FL, NC, NY, TX
  • Clear Street LLC (CRD 288933) · New York, New YorkSold in all US states

Signed by Susan L. Drexler, Interim Chief Financial Officer. Newest notice filed Nov 16, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$30 MNo. 4$10 to $50 million

Aileron Therapeutics Inc.: Raise no. 4, Dec 2016

Investors in this round

11 investors had bought by the notice of Jan 6, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Aileron Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $40 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph A. Yanchik III · Executive Officer, Director
  • Manuel H. Aivado · Executive Officer
  • Armen H. Shanafelt · Director
  • Brian M. Gallagher, Jr. · Director
  • Caleb H. Winder · Director
  • John H. McArthur · Director
  • Reinhard J. Ambros · Director
  • Scott L. Kapnick · Director
  • Seth L. Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph A. Yanchik III, President and Chief Executive Officer. Newest notice filed Jan 6, 2017. Read the notice at the SEC.

equitySEC
Oct 2014$20 MNo. 3$10 to $50 million

Aileron Therapeutics Inc.: Raise no. 3, Oct 2014

Investors in this round

13 investors had bought by the notice of Oct 29, 2014: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Aileron Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $33 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph A. Yanchik III · Executive Officer, Director
  • Armen H. Shanafelt · Director
  • Brian M. Gallagher, Jr. · Director
  • Enrico H. Petrillo · Director
  • John H. McArthur · Director
  • Reinhard J. Ambros · Director
  • Scott L. Kapnick · Director
  • Seth L. Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph A. Yanchik III, President and Chief Executive Officer. Newest notice filed Oct 29, 2014. Read the notice at the SEC.

equitySEC
Nov 2013$15 MNo. 2$10 to $50 million

Aileron Therapeutics Inc.: Raise no. 2, Nov 2013

Investors in this round

11 investors had bought by the notice of Nov 19, 2013: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Aileron Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph A. Yanchik III · Executive Officer, Director
  • Brian M. Gallagher, Jr. · Director
  • Enrico H. Petrillo · Director
  • John H. McArthur · Director
  • Reinhard J. Ambros · Director
  • Scott L. Kapnick · Director
  • Seth L. Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph A. Yanchik III, President and Chief Executive Officer. Newest notice filed Nov 19, 2013. Read the notice at the SEC.

equitySEC
May 2009$28 MNo. 1$10 to $50 million

Aileron Therapeutics Inc.: Raise no. 1, May 2009

Investors in this round

8 investors had bought by the notice of Jun 12, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Aileron Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $40 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph A. Yanchik III · Executive Officer, Director
  • Campbell Murray · Director
  • Enrico Petrillo · Director
  • Michael Diem · Director
  • Seth Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph A. Yanchik III, President and Chief Executive Officer. Newest notice filed Jun 12, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aileron Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).

    SEC Form D · Nov 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2023

Products and services#

No products or services of Aileron Therapeutics Inc. are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Aileron Therapeutics Inc.
InvestorKindAmountRoundRoleSource
AJU IB Investment Co., Ltd.Fund or asset managernot statednot statedHeld Series E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Apple Tree Partners II - Annex, L.P.Fund or asset managernot statednot statedHeld Series E and E-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Apple Tree Partners II LPFund or asset managernot statednot statedHeld Series A, A-1, B, C, C-2 and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
CVF LLCOthernot statednot statedHeld Series E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Excel Medical Fund LPFund or asset managernot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Excel Medical Ventures, LLCVenture capitalnot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
James Brian WindsorPersonnot statednot statedHeld Series X preferred stock (Form 3, 2023)SEC Form 3
Jon B. PlattPersonnot statednot statedHeld Series C-2, D, E and E-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
KCK LTD.Companynot statednot statedHeld Series E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lilly Ventures Fund I LLCVenture capitalnot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
LV Management Group, LLCFund or asset managernot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Novartis AGCompanynot statednot statedHeld Series C, C-2, D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Novartis Bioventures LtdVenture capitalnot statednot statedHeld Series C, C-2, D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Roche Finance LTDCompanynot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Roche Holding LTDCompanynot statednot statedHeld Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Scott KapnickPersonnot statednot statedHeld Series D, D-1, E-2, E-3 and F preferred (Form 3, 2017)SEC Form 3
Sigma Emerging Markets Ltd.Companynot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Largest shareholders today

Institutions holding Rein Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aileron Therapeutics Inc.
NameRoleNamed in
Brian L. Windsor, Ph.D.Executive officerNov 2023
Manuel Alves-Aivado, M.D., Ph.D.Executive officerNov 2023
Susan L. DrexlerExecutive officerNov 2023
Joseph A. Yanchik IIIExecutive officerJan 2017
Manuel H. AivadoExecutive officerJan 2017
Alan H. MussoDirectorNov 2023
Josef H. von RickenbachDirectorNov 2023
Manuel Alves-Aivado, M.D., Ph.D.DirectorNov 2023
Nolan H. Sigal, M.D., Ph.D.DirectorNov 2023
Reinhard J. AmbrosDirectorNov 2023
William H. FaireyDirectorNov 2023
Armen H. ShanafeltDirectorJan 2017
Brian M. Gallagher, Jr.DirectorJan 2017
Caleb H. WinderDirectorJan 2017
John H. McArthurDirectorJan 2017
Joseph A. Yanchik IIIDirectorJan 2017
Scott L. KapnickDirectorJan 2017
Seth L. HarrisonDirectorJan 2017
Enrico H. PetrilloDirectorOct 2014
Campbell MurrayDirectorJun 2009
Enrico PetrilloDirectorJun 2009
Michael DiemDirectorJun 2009
Seth HarrisonDirectorJun 2009

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.